Bioventix PLC
LSE:BVXP
Intrinsic Value
Bioventix Plc engages in the development and supply of antibodies. [ Read More ]
The intrinsic value of one BVXP stock under the Base Case scenario is 2 821.06 GBX. Compared to the current market price of 4 600 GBX, Bioventix PLC is Overvalued by 39%.
Valuation Backtest
Bioventix PLC
Run backtest to discover the historical profit from buying and selling BVXP stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Bioventix PLC
Current Assets | 12m |
Cash & Short-Term Investments | 5.5m |
Receivables | 5.9m |
Other Current Assets | 585.7k |
Non-Current Assets | 1.1m |
Long-Term Investments | 610k |
PP&E | 522.7k |
Current Liabilities | 1.7m |
Accounts Payable | 1.7m |
Non-Current Liabilities | 6.7k |
Other Non-Current Liabilities | 6.7k |
Earnings Waterfall
Bioventix PLC
Revenue
|
13.6m
GBP
|
Cost of Revenue
|
-850.5k
GBP
|
Gross Profit
|
12.7m
GBP
|
Operating Expenses
|
-2m
GBP
|
Operating Income
|
10.8m
GBP
|
Other Expenses
|
-2.1m
GBP
|
Net Income
|
8.7m
GBP
|
Free Cash Flow Analysis
Bioventix PLC
What is Free Cash Flow?
BVXP Profitability Score
Profitability Due Diligence
Bioventix PLC's profitability score is 86/100. The higher the profitability score, the more profitable the company is.
Score
Bioventix PLC's profitability score is 86/100. The higher the profitability score, the more profitable the company is.
BVXP Solvency Score
Solvency Due Diligence
Bioventix PLC's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Bioventix PLC's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BVXP Price Targets Summary
Bioventix PLC
According to Wall Street analysts, the average 1-year price target for BVXP is 6 018 GBX with a low forecast of 5 959 GBX and a high forecast of 6 195 GBX.
Shareholder Return
BVXP Price
Bioventix PLC
Average Annual Return | 7.81% |
Standard Deviation of Annual Returns | 29.95% |
Max Drawdown | -35% |
Market Capitalization | 240.1m GBX |
Shares Outstanding | 5 219 660 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Bioventix Plc engages in the development and supply of antibodies. The company is headquartered in Farnham, Surrey and currently employs 17 full-time employees. The company went IPO on 2014-04-29. The principal activity of the Company is the development and supply of antibodies. The firm specializes in the development of sheep monoclonal antibodies (SMAs) for use in immunodiagnostics focusing on the areas of clinical diagnostics, such as in automated immunoassays used in blood testing. The firm offers a portfolio of antibodies to customers for both commercial use and research and development (R&D) purposes, for the diagnosis or monitoring of a range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. The firm also supplies antibody products and services to multinational clinical diagnostics companies. The firm sells its products through direct sales and through distributors.
Contact
IPO
Employees
Officers
The intrinsic value of one BVXP stock under the Base Case scenario is 2 821.06 GBX.
Compared to the current market price of 4 600 GBX, Bioventix PLC is Overvalued by 39%.